021-51111890
购物车（）
sales@molnova.cn
Eletriptan
CAS No. 143322-58-1
Eletriptan ( UK 116044 )
产品货号. M11842 CAS No. 143322-58-1
Eletriptan (UK 116044) 是一种有效的、选择性的、口服活性的 5-HT1B/1D 受体激动剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2271 | 有现货 |
|
| 10MG | ￥3192 | 有现货 |
|
| 50MG | ￥15438 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Eletriptan
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Eletriptan (UK 116044) 是一种有效的、选择性的、口服活性的 5-HT1B/1D 受体激动剂。
-
产品描述Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist; significantly increases occluded wedge pressure and mean pulmonary artery pressure in vivo, with no significant coronary artery constriction, and obstructive coronary artery disease; displays antimigraine activity.Migraine Approved.
-
体外实验——
-
体内实验Eletriptan (10, 30, 100, 300 and 1000 μg/kg; i.v.) reduces total carotid blood flow in anaesthetised pigs by selectively reducing carotid arteriovenous anastomotic blood flow and increasing nutrient blood flow within the carotid vascular bed.
-
同义词UK 116044
-
通路GPCR/G Protein
-
靶点5-HT Receptor
-
受体5-HT Receptor
-
研究领域Neurological Disease
-
适应症Migraine
化学信息
-
CAS Number143322-58-1
-
分子量382.52
-
分子式C22H26N2O2S
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCN1CCC[C@@H]1Cc2c[nH]c3c2cc(cc3)CCS(=O)(=O)c4ccccc4
-
化学全称3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Napier C, et al. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.
2. Gupta P, et al. Eur J Pharmacol. 1999 Feb 19;367(2-3):283-90.
3. Muir DF, et al. Clin Pharmacol Ther. 1999 Jul;66(1):85-90.
产品手册
关联产品
-
Lumateperone
Lumateperone (ITI-007) 是一种有效的 5-HT2A 拮抗剂 (Ki=0.54 nM)、突触后 D2 拮抗剂 (Ki=32 nM) 和 SERT 阻滞剂 (Ki= 61 nM)。
-
Ebalzotan
Ebalzotan (NAE 086) is a 5-HT1A receptor agonist that can be used to study depression.
-
Capeserod
Capeserod is a potential 5-HT4 receptor (5-hydroxytryptamine receptor 4) agonist for the study of digestive disorders and neurological disorders.
